Abstract | BACKGROUND AND OBJECTIVE: PATIENTS AND METHODS: The medical ethics committee in Tokushima University Hospital approved protocol for this study. Sixteen patients with AA (more than 5 cm in diameter, scheduled open surgery) were divided into two groups; one is PPAR-γ agonist administrating group [Formula: see text] n = 6, group P[Formula: see text], and another is the without group [Formula: see text] n = 10, group C[Formula: see text]. PPAR-γ agonist, whose dose was 15 mg/day, was administrated in the group P for more than 2 months before aneurysectomy and grafting (mean; 4.2 ± 3.4 months) (Supplemental Table 1). Biopsy specimens were obtained from abdominal subcutaneous fat, greater omentum, retroperitoneal periaortic fat and aneurysmal wall in surgical procedure. Blood examination also achieved before/after procedure. Harvested specimens were analyzed with histology (HE and EVG), immunohistochemistry (macrophage) and RT-PCR ( adiponectin, MCP-1, TNF-α, CD68, matrix metalloprotease ( MMP)-2, MMP-9). RESULTS: Macrophage infiltration in aortic wall and retroperitoneal periaortic fat among group P was significantly decreased compared to that among group C. Adiponectin expressions in both subcutaneous fat and retroperitoneal periaortic fat among the group P ( adiponectin/β-actin) were significantly increased compared to those among the group C [subcutaneous fat; 16.8 ± 13.9 vs. 5.82 ± 2.94 (P = 0.04), retroperitoneal periaortic fat; 21.3 ± 24.1 vs. 2.12 ± 1.69 (P = 0.04)]. On the other hand, expressions of TNF-α, and MMP-9 in both aortic aneurysmal wall and retroperitoneal periaortic fat among group P were significantly decreased. [(Aortic aneurysmal wall; TNF-α; 0.45 ± 0.15 vs. 5.18 ± 3.49 (P = 0.02), MMP-9; 39.6 ± 69.0 vs. 721 ± 741 (P = 0.04)], [retroperitoneal periaortic fat; TNF-α; 1.14 ± 0.36 vs. 26.4 ± 25.0 (P = 0.048), MMP-9; 0.18 ± 0.21 vs. 50.0 ± 41.8 (P = 0.047)]. CONCLUSION: These data may indicate that PPAR-γ agonist become the way for preventing or delaying aortic aneurysm progression in patients. More studies will be needed to clarify this drug effects in detail.
|
Authors | Tatsuo Motoki, Hirotsugu Kurobe, Yoichiro Hirata, Taisuke Nakayama, Hajime Kinoshita, Kevin A Rocco, Hitoshi Sogabe, Takaki Hori, Masataka Sata, Tetsuya Kitagawa |
Journal | General thoracic and cardiovascular surgery
(Gen Thorac Cardiovasc Surg)
Vol. 63
Issue 10
Pg. 565-71
(Oct 2015)
ISSN: 1863-6713 [Electronic] Japan |
PMID | 26213347
(Publication Type: Journal Article)
|
Chemical References |
- Hypoglycemic Agents
- PPAR gamma
- Thiazolidinediones
- Pioglitazone
|
Topics |
- Aged
- Aortic Aneurysm
(diagnosis, drug therapy)
- Aortitis
(diagnosis, drug therapy)
- Female
- Humans
- Hypoglycemic Agents
(therapeutic use)
- Male
- PPAR gamma
(agonists)
- Pioglitazone
- Thiazolidinediones
(therapeutic use)
|